(SOLV) Solventum - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US83444M1018
SOLV: Wound Care, Dental Products, Medical Software, Filtration Systems
Solventum Corporation, listed on the NYSE as SOLV, stands as a beacon in the healthcare sector, navigating through the complexities of modern medicine with a diversified portfolio. This young company, incorporated in 2023 and headquartered in Saint Paul, Minnesota, is strategically positioned to address critical healthcare needs across four distinct segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Each segment is a pillar in Solventums mission to enhance patient outcomes and streamline healthcare operations.
The Medsurg segment is a cornerstone of Solventums offerings, providing essential medical solutions that are vital for patient care and safety. Products such as advanced wound care and IV site management are not just tools but lifelines, addressing the growing need for effective and reliable medical supplies. This segment underscores the companys commitment to innovation in patient care, ensuring that healthcare providers have the
Additional Sources for SOLV Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SOLV Stock Overview
| Market Cap in USD | 13,464m |
| Sector | Healthcare |
| Industry | Health Information Services |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 2024-03-26 |
SOLV Stock Ratings
| Growth 5y | 3.66% |
| Fundamental | 13.4% |
| Dividend | 0.0% |
| Rel. Strength Industry | -7.87 |
| Analysts | 3.09/5 |
| Fair Price Momentum | 67.46 USD |
| Fair Price DCF | 107.53 USD |
SOLV Dividends
No Dividends PaidSOLV Growth Ratios
| Growth Correlation 3m | 83.3% |
| Growth Correlation 12m | 71.9% |
| Growth Correlation 5y | 71.9% |
| CAGR 5y | -7.49% |
| CAGR/Max DD 5y | -0.19 |
| Sharpe Ratio 12m | -0.88 |
| Alpha | -13.15 |
| Beta | 0.27 |
| Volatility | 28.39% |
| Current Volume | 1042.2k |
| Average Volume 20d | 1080.5k |
As of March 13, 2025, the stock is trading at USD 74.01 with a total of 1,042,167 shares traded.
Over the past week, the price has changed by -4.91%, over one month by +0.45%, over three months by +5.71% and over the past year by -7.49%.
Neither. Based on ValueRay Fundamental Analyses, Solventum is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 13.39 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SOLV as of March 2025 is 67.46. This means that SOLV is currently overvalued and has a potential downside of -8.85%.
Solventum has received a consensus analysts rating of 3.09. Therefor, it is recommend to hold SOLV.
- Strong Buy: 1
- Buy: 0
- Hold: 9
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, SOLV Solventum will be worth about 72.9 in March 2026. The stock is currently trading at 74.01. This means that the stock has a potential downside of -1.57%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 79.9 | 7.9% |
| Analysts Target Price | 69.7 | -5.9% |
| ValueRay Target Price | 72.9 | -1.6% |